Eli Lilly (LLY) believes its experimental weight-loss pill could make GLP-1 treatments more accessible worldwide.

On Thursday, Jim Cramer, the host of Mad Money, discussed the recent turbulence in the stock market, pointing to the lack of ...

That negative investor reaction was directed at companies involved in the white-hot weight loss drug segment of the market (Eli Lilly is the pharmaceutical giant behind a popular one, Zepbound).

Eli Lilly on Wednesday said it will invest at least ... including Kevin Hassett, director of the White House National Economic Council, and Commerce Secretary Howard Lutnick, who explicitly ...

The new US investment, announced by Eli Lilly at an event held near the White House on Wednesday, marks the latest effort by the pharmaceutical company to ingratiate itself with the Trump ...

After scoring a long-awaited FDA approval last fall, Eli Lilly has launched a consumer ... the immunology drug in people who identify as non-white and have plaque psoriasis and scalp psoriasis.

Eli Lilly LLY.N plans to spend at least $27 billion ... Despite telling Republicans in a White House meeting earlier this month that he was considering such an exemption, Reuters reported ...